LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 1 of total 1

Search options

Article ; Online: Seed amplification and neurodegeneration marker trajectories in individuals at risk of prion disease.

Mok, Tze How / Nihat, Akin / Majbour, Nour / Sequeira, Danielle / Holm-Mercer, Leah / Coysh, Thomas / Darwent, Lee / Batchelor, Mark / Groveman, Bradley R / Orr, Christina D / Hughson, Andrew G / Heslegrave, Amanda / Laban, Rhiannon / Veleva, Elena / Paterson, Ross W / Keshavan, Ashvini / Schott, Jonathan M / Swift, Imogen J / Heller, Carolin /
Rohrer, Jonathan D / Gerhard, Alexander / Butler, Christopher / Rowe, James B / Masellis, Mario / Chapman, Miles / Lunn, Michael P / Bieschke, Jan / Jackson, Graham S / Zetterberg, Henrik / Caughey, Byron / Rudge, Peter / Collinge, John / Mead, Simon

Brain : a journal of neurology

2023  Volume 146, Issue 6, Page(s) 2570–2583

Abstract: Human prion diseases are remarkable for long incubation times followed typically by rapid clinical decline. Seed amplification assays and neurodegeneration biofluid biomarkers are remarkably useful in the clinical phase, but their potential to predict ... ...

Abstract Human prion diseases are remarkable for long incubation times followed typically by rapid clinical decline. Seed amplification assays and neurodegeneration biofluid biomarkers are remarkably useful in the clinical phase, but their potential to predict clinical onset in healthy people remains unclear. This is relevant not only to the design of preventive strategies in those at-risk of prion diseases, but more broadly, because prion-like mechanisms are thought to underpin many neurodegenerative disorders. Here, we report the accrual of a longitudinal biofluid resource in patients, controls and healthy people at risk of prion diseases, to which ultrasensitive techniques such as real-time quaking-induced conversion (RT-QuIC) and single molecule array (Simoa) digital immunoassays were applied for preclinical biomarker discovery. We studied 648 CSF and plasma samples, including 16 people who had samples taken when healthy but later developed inherited prion disease (IPD) ('converters'; range from 9.9 prior to, and 7.4 years after onset). Symptomatic IPD CSF samples were screened by RT-QuIC assay variations, before testing the entire collection of at-risk samples using the most sensitive assay. Glial fibrillary acidic protein (GFAP), neurofilament light (NfL), tau and UCH-L1 levels were measured in plasma and CSF. Second generation (IQ-CSF) RT-QuIC proved 100% sensitive and specific for sporadic Creutzfeldt-Jakob disease (CJD), iatrogenic and familial CJD phenotypes, and subsequently detected seeding activity in four presymptomatic CSF samples from three E200K carriers; one converted in under 2 months while two remain asymptomatic after at least 3 years' follow-up. A bespoke HuPrP P102L RT-QuIC showed partial sensitivity for P102L disease. No compatible RT-QuIC assay was discovered for classical 6-OPRI, A117V and D178N, and these at-risk samples tested negative with bank vole RT-QuIC. Plasma GFAP and NfL, and CSF NfL levels emerged as proximity markers of neurodegeneration in the typically slow IPDs (e.g. P102L), with significant differences in mean values segregating healthy control from IPD carriers (within 2 years to onset) and symptomatic IPD cohorts; plasma GFAP appears to change before NfL, and before clinical conversion. In conclusion, we show distinct biomarker trajectories in fast and slow IPDs. Specifically, we identify several years of presymptomatic seeding positivity in E200K, a new proximity marker (plasma GFAP) and sequential neurodegenerative marker evolution (plasma GFAP followed by NfL) in slow IPDs. We suggest a new preclinical staging system featuring clinical, seeding and neurodegeneration aspects, for validation with larger prion at-risk cohorts, and with potential application to other neurodegenerative proteopathies.
MeSH term(s) Humans ; tau Proteins/metabolism ; Prion Diseases ; Creutzfeldt-Jakob Syndrome ; Prions ; Biomarkers
Chemical Substances tau Proteins ; Prions ; Biomarkers
Language English
Publishing date 2023-03-25
Publishing country England
Document type Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID 80072-7
ISSN 1460-2156 ; 0006-8950
ISSN (online) 1460-2156
ISSN 0006-8950
DOI 10.1093/brain/awad101
Shelf mark
Ui II Zs.26: Show issues Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)
Database MEDical Literature Analysis and Retrieval System OnLINE

More links

Kategorien

To top